PDCD1 and neoplasm: Anti-PD-1/PD-L1 inhibitors reduce the expression level of PD-1/PD-L1 or promote the degradation of PD-1/PD-L1 to block the binding of PD-1 with PD-L1, restoring the body’s immune system to recognize and attack tumor cells again [118].